改善慢性乙型肝炎病毒感染的临床结果

StephenW

Perspective
Improving clinical outcomes of chronic hepatitis B virus infection
Tung-Hung Su & Jia-Horng Kao
Pages 141-154 | Published online: 22 Sep 2014

    Download citation http://dx.doi.org/10.1586/17474124.2015.960398



Abstract

Chronic hepatitis B virus (HBV) infection is a global health problem, leading to cirrhosis, hepatocellular carcinoma (HCC) and liver-related deaths. Universal hepatitis B vaccination is the most cost–effective way to eradicate HBV infection with the remarkable reduction of chronic carriage, neonatal fulminant hepatitis and childhood HCC. The introduction of highly effective antiviral agents, including lamivudine, adefovir dipivoxil, entecavir, telbivudine, tenofovir disoproxil fumarate and pegylated interferons further improve short-, medium- and long-term outcomes of chronic HBV infection, such as ALT normalization, HBV DNA suppression, HBeAg seroconversion, HBsAg seroclearance, fibrosis regression, reduction of cirrhosis, HCC, liver-related deaths and the need for liver transplantation. Above all, sustained and profound viral suppression is the key to improve the clinical outcomes of chronic hepatitis B.
Keywords: adefovir dipivoxil, cirrhosis, entecavir, hepatocellular carcinoma, interferon, lamivudine, liver transplantation, telbivudine, tenofovir disoproxil fumarate, vaccination

StephenW

透视
改善慢性乙型肝炎病毒感染的临床结果
苏东红，姜家宏
页141-154 |网上发布：2014年9月22日

    下载引文http://dx.doi.org/10.1586/17474124.2015.960398



抽象

慢性乙型肝炎病毒（HBV）感染是全球性的健康问题，导致肝硬化，肝细胞癌（HCC）和肝脏相关的死亡。普遍的乙肝疫苗接种是根除慢性运输，新生儿暴发性肝炎和儿童HCC显着减少的根除HBV感染的最具成本效益的方法。包括拉米夫定，阿德福韦酯，恩替卡韦，替比夫定，富马酸替诺福韦酯和聚乙二醇干扰素在内的高效抗病毒药物的引入进一步改善了慢性HBV感染的短期，中期和长期预后，如ALT正常化，HBV DNA抑制， HBeAg血清学转换，HBsAg血清学清除，纤维化消退，肝硬化减少，HCC，肝脏相关性死亡以及肝移植的需求。最重要的是，持续而深刻的病毒抑制是改善慢性乙型肝炎临床结果的关键。
关键词：阿德福韦酯，肝硬化，恩替卡韦，肝细胞癌，干扰素，拉米夫定，肝移植，替比夫定，替诺福韦酯，富马酸替诺福韦，免疫

Hepbest

最重要的是，持续而深刻的病毒抑制是改善慢性乙型肝炎临床结果的关键。
——持续而深刻的病毒抑制， 即病毒一直持续抑制到不可测